17:54 , Jul 26, 2017 |  BC Innovations  |  Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd.’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of therapies...
19:44 , Apr 14, 2017 |  BC Week In Review  |  Company News

2-BBB Medicines, TTY Biopharm deal

The companies formed a joint venture in Taiwan to develop and commercialize 2-BBB’s multiple sclerosis candidate 2B3-201. 2-BBB will grant the JV exclusive rights to 2B3-201 and will receive a 33.3% stake in the JV;...
19:46 , Mar 31, 2017 |  BC Week In Review  |  Company News

2-BBB, Oncology Venture deal

2-BBB granted Oncology Venture exclusive, worldwide rights to develop and commercialize 2X-111 (formerly 2B3-101) to treat cancer. The pegylated liposomal doxorubicin conjugated with glutathione has completed a Phase II trial to treat solid tumors, including...
08:00 , Nov 12, 2015 |  BC Innovations  |  Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
01:56 , Feb 19, 2015 |  BC Extra  |  Company News

Management tracks

Lycera Corp. (Ann Arbor, Mich.) named Paul Sekhri president, CEO and director, effective immediately. Sekhri was SVP of integrated care at Sanofi (Euronext:SAN; NYSE:SNY). Pharming Group N.V. (Euronext:PHARM) hired Perry Calias as CSO, effective immediately....
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

BBB Therapeutics management update

BBB Therapeutics B.V., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Resigned: Anders Harfstrand as CEO   ...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

BBB Therapeutics management update

BBB Therapeutics B.V., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Ferdinand Massari as CMO, formerly SVP and CMO of ImmusanT Inc.   Transitioned: Pericles Calias to CSO from SVP of translational medicine   ...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

2B3-201: Phase I data

A double-blind, crossover, Dutch Phase I trial in 18 healthy male volunteers showed that single ascending doses of up to 450 mg 2B3-201 were well tolerated with no serious adverse events reported. Subjects received an...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

to-BBB management update

to-BBB technologies B.V., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A.; he succeeds interim CEO Leonard Kruimer, who remains CFO   ...